Trials / Terminated
TerminatedNCT01402401
Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients
An Open-label, Single-arm, Multi-center Phase II Study to Evaluate the Efficacy and Safety of AUY922 in Combination With Trastuzumab Standard Therapy as Second-line Treatment in Patients With HER2-positive Advanced Gastric Cancer
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the safety and efficacy of AUY922, when administered, in combination with trastuzumab in adult patients with HER2+ advanced gastric cancer, who have received trastuzumab plus chemotherapy in the first line.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AUY922 | |
| DRUG | Trastuzumab |
Timeline
- Start date
- 2011-11-01
- Primary completion
- 2013-06-01
- Completion
- 2013-06-01
- First posted
- 2011-07-26
- Last updated
- 2020-12-10
Locations
15 sites across 8 countries: United States, Belgium, France, Germany, Italy, Japan, South Korea, Spain
Source: ClinicalTrials.gov record NCT01402401. Inclusion in this directory is not an endorsement.